

Research paper

Evaluation of *in vitro* and *in vivo* antibacterial activity of novel Cu(II)-steroid complexesStephen Barrett^a, Stephen Delaney^b, Kevin Kavanagh^{b,*}, Diego Montagner^{a,*}^a Department of Chemistry, Maynooth University, Maynooth, Ireland^b Department of Biology, Maynooth University, Maynooth, Ireland

ARTICLE INFO

Article history:

Received 30 March 2018

Received in revised form 24 April 2018

Accepted 25 April 2018

Available online 26 April 2018

Dedicated to Ms. Elena Bertacco, former PhD student of D.M.

Keywords:

Copper(II)

Phenanthroline

Steroids

Antimicrobial

In vivo

ABSTRACT

A pioneer series of copper(II) complexes bearing planar phenanthroline-modified aromatic ligands and steroid (ethynylestradiol and ethisterone) with generic formula $[\text{Cu}(\text{N}\cap\text{N})(\text{steroid})](\text{NO}_3)_2$ where $\text{N}\cap\text{N}$ is DPQ, DPPZ and DPPN and steroid is estradiol or testosterone, were synthesized, characterised and screened *in vitro* and *in vivo* as antimicrobial agents against *Staphylococcus aureus* and methicillin resistant *Staphylococcus aureus* (MRSA). Toxicity studies revealed notable antibacterial activity of the copper – based compounds, which is significantly increased *in vivo* by the presence of the steroid moiety. Toxicity profiling was estimated *in vitro* versus Gram-positive (*Staphylococcus aureus*) and MRSA and *in vivo* in *Galleria mellonella* larvae infected with *S. aureus*. Results showed the complexes to be active against *S. aureus* and MRSA *in vitro* (MIC₅₀ average value of 2.46 and 97 μM in *S. aureus* and MRSA, respectively) and to be active when larvae infected with *S. aureus* were administered the agents.

© 2018 Elsevier B.V. All rights reserved.


1. Introduction

The bacterium *Staphylococcus aureus* is a Gram positive body commensal which has the ability to survive in a wide variety of environments [1], and this contributes to its ability to induce a range of superficial and systemic infections. *S. aureus* possesses a number of virulence factors that contribute to its ability to colonise tissue including the presence of a capsule, the expression of adhesins, the secretion of a range of toxins and immunomodulators which disrupt the host's immune response [2]. This bacterium is present on approximately 30% of healthy individuals in the anterior nares and on the skin, but a skin breach resulting from surgery or trauma can result in a variety of skin infections, such as impetigo, or more serious diseases such as toxic shock syndrome and sepsis [3,4]. *S. aureus* infection can be extremely difficult to treat and up to 4% of cases can be fatal [3]. Treatment of *S. aureus* infections is hindered by the emergence of methicillin-resistant *S. aureus* (MRSA) and due to the increasing incidence of resistance to conventional antimicrobials there is a renewed interest in the development of novel metal based drugs as antimicrobial agent [5].

Despite the classic organic based antibacterial agents, metal complexes are an excellent alternative and in particular Cu(phen) derivatives. In the last twenty years the antimicrobial activity of

Cu(phen) complexes have been deeply investigated; double charged copper with planar chelating ligands exhibit growth inhibitory activity against *Staphylococcus aureus* (MIC ≥ 4.0 –7.9 μM) and to a lesser extent against *Escherichia coli* [6–13]. It is still not completely clear what role the planar ligands play in the antimicrobial activity of the corresponding metal based drugs. Indeed, metal complexes with substituted planar aromatic ligands (i.e. DPQ, DPPZ and DPPN, Scheme 1) show an increased interaction via intercalation with the DNA and Cu(II) derivatives and also show artificial nuclease activity but this could not be related with the antimicrobial properties [14–16]. Mitochondrial membrane damage and p53 upregulation are also alternative possible pathways of action. Creaven et al. showed that Cu(phen) complexes functionalised with acetic acids are able to inhibit respiration, reduce level of ergosterol and alter the cytochrome c content [12]. Considering these aspects, here we report the syntheses, characterization and antimicrobial evaluation of a series of Cu(II) complexes with chelating planar ligands further functionalised with steroids (testosterone and estradiol). We recently showed that the modification of Au(I)–NHC (*N*-Heterocyclic Carbenes) with steroids derivatives is a promising strategy to enhance the antibacterial activity of the related complexes [17]. In the work presented here the Cu(II) cationic complexes were evaluated as antibacterial agents *in vitro* against *S. aureus* and MRSA and *in vivo* using *Galleria mellonella* larvae.

* Corresponding authors.



Scheme 1. Structures of $[\text{Cu}(\text{ES-5-phen})(\text{DPQ})]^{2+}$ **4**, $[\text{Cu}(\text{EE-5-phen})(\text{DPQ})]^{2+}$ **5**, $[\text{Cu}(\text{ES-5-phen})(\text{DPPZ})]^{2+}$ **6**, $[\text{Cu}(\text{EE-5-phen})(\text{DPPZ})]^{2+}$ **7**, $[\text{Cu}(\text{ES-5-phen})(\text{DPPN})]^{2+}$ **8**, $[\text{Cu}(\text{EE-5-phen})(\text{DPPN})]^{2+}$ **9**.

The immune system of insects shows many structural and functional similarities to the innate immune response of mammals [18–20] and consequently insects can be used to assess the virulence of microbial pathogens or the *in vivo* efficacy of antimicrobial drugs and give results similar to those obtained using mammals [21,22]. Larvae of *Galleria mellonella* are a popular choice for these types of tests and are inexpensive to purchase, and give rapid results [18]. *G. mellonella* larvae have previously been used to demonstrate the *in vivo* activity of novel metal based drugs against pathogenic bacteria and fungi [23,24] and show a strong correlation with results obtained in rats [25].

The aim of this work was to analyse the *in vitro* effects of the six metal complexes on *Staphylococcus aureus* and MRSA, to evaluate the toxicity of the compounds in *Galleria mellonella* larvae and to examine if the compounds showed any therapeutic properties when larvae had been pre-inoculated with microbial infections.

2. Material and methods

All reagents and reactants used were purchased from commercial sources. The two sources used were Sigma Aldrich and Tokyo Chemical Industry. DPQ (Dipyrido[3,2-*f*:2',3'-*h*]quinoxaline), DPPZ (Dipyrido[3,2-*a*:2',3'-*c*]phenazine), DPPN (Benzo[1]dipyrido[3,2-*a*:2',3'-*c*]phenazine) and tetrakis triphenylphosphine Palladium(0) were synthesized as previously reported [26–29].

All solvents were used without further purification. The DMF was dried using 4 Å molecular sieves, it was then decanted into a round bottom flask and kept under high vacuum using a Schlenk line while immersed in liquid nitrogen. The DMF was then flushed with nitrogen gas. This step was repeated a minimum of three times for the Sonogashira coupling reaction to obtain ES-5-phen and EE-5-phen.

All NMR spectra were recorded on a Bruker Advance spectrometer with the probe at 293 K, operating at 500 MHz for the ^1H nucleus. Proton signals were assigned with the help of 2D NMR experiments (COSY). Spectra were recorded in CDCl_3 using Me_4Si as the internal standard. All chemical shifts are reported in ppm.

Infrared (IR) spectra were recorded in the region 4000 – 400 cm^{-1} on a Perkin Elmer precisely spectrum 100 FT/IR spectrometer. The solid samples were run using ATR.

Elemental analyses (carbon, hydrogen and nitrogen) were performed with a PerkinElmer 2400 series II analyzer. ESI mass spec-

tra were recorded in positive mode with a Waters LCT Premier XE Spectrometer.

2.1. Assessment of antibacterial activity of novel complexes

The complexes were dissolved in 1 mL DMSO to give a stock concentration of 5 mg/mL. Nutrient broth (100 μL) was added to each well of a 96 well plate. Each drug was serially diluted on the plate giving a concentration range 150 – 0.59 μM . Bacteria were grown overnight and the OD_{600} was adjusted to 0.1 (equivalent to cell density of $4 \times 10^7/\text{ml}$). Bacterial cells (100 μL) were added to each well and the growth was measured at 600 nm after 24 h at 37 °C using a spectrophotometer (BioPhotometer). The MIC_{50} values were calculated as the minimum concentration of drug that inhibited growth by 50%.

2.2. Inoculation of *Galleria mellonella* larvae

Sixth instar larvae of *G. mellonella* (Lepidoptera: Pyralidae, the Greater Wax Moth) (Mealworm Company, Sheffield, England) were stored in the dark at 15 °C. 5 Larvae of the same age and weighing 0.3 g were inoculated with 20 μL of PBS containing cells 4×10^7 bacterial cell through the last pro-leg using a Myjector U100 insulin syringe (Terumo Europe, Leuven, Belgium).

2.3. *In vivo* toxicity assay

Larvae were injected with 20 μL of compound solution (150 – 0.59 μM) or 5% (v/v) DMSO through the last left pro-leg as described. Larvae were incubated at 37 °C for 24 h prior to quantifying survival after 24, 48 and 72 h.

2.4. Effect of compounds on survival of *G. Mellonella* larvae infected with *S. aureus*

Larvae were injected with *S. aureus* through the last left proleg as described. One hour post infection 20 μL of each compound solution (0.1 or 0.25 mg/ml) was administered. The control consisted of larvae inoculated with the *S. aureus*. Larvae were incubated at 37 °C and survival was assessed at 24 and 48 h.

3. Experimental

The starting $[\text{Cu}(\text{N} \cap \text{N})(\text{OH}_2)_2](\text{NO}_3)_2$ (**1–3**) complexes (where $\text{N} \cap \text{N}$ is DPQ (**1**), DPPZ (**2**) or DPPN(**3**), See Experimental Part in Supporting Information) were obtained by modifying a literature procedure [21–23]. Briefly, $\text{Cu}(\text{NO}_3)_2 \cdot 3\text{H}_2\text{O}$ and the corresponding $\text{N} \cap \text{N}$ ligand where mixed in a 1.1 to 1 ratio in methanol and refluxed for two hours. The slight excess of the Copper salt prevent the formation of the more stable bis-adduct $[\text{Cu}(\text{N} \cap \text{N})_2](\text{NO}_3)_2$. The solid was obtained by addition of Et_2O , isolated by filtration and dried in vacuum (Supporting Information).

The phen-steroid derivatives of general formula ES or EE-5-phen (where ES-5-phen and EE-5-phen are the Estradiol and Testosterone derivatives, respectively) have been obtained by Sonogashira coupling reaction between 5-Bromophenanthroline and the correspondent commercial available alkyne derivative of the steroids (See Scheme 2 and Supporting Information).

The final complexes $[\text{Cu}(\text{N} \cap \text{N})(\text{EE or ES-5-phen})](\text{NO}_3)_2$ (**4–9**) are depicted in Scheme 1 and were obtained by mixing the corresponding $[\text{Cu}(\text{N} \cap \text{N})(\text{OH}_2)_2](\text{NO}_3)_2$ (**1–3**) and the corresponding steroid-phen in a 1 to 1 ratio in DMF at 50 °C overnight. The solids were isolated by filtration after addition of Et_2O and dried in vacuum (See Supporting Information).

Download English Version:

<https://daneshyari.com/en/article/7750448>

Download Persian Version:

<https://daneshyari.com/article/7750448>

[Daneshyari.com](https://daneshyari.com)